DOCSLIB.ORG

2020 Interim Results Presentation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2020 Interim Results Presentation Disclaimer The sole purpose of this Presentation (the “Presentation”) is to assist the recipient in deciding whether it wishes to proceed with a further investigation of Sihuan Pharmaceutical Holdings Group Ltd. (the “Company”) and it is not intended to form the basis of any decision to purchase securities, interests or assets in or of the Company. This Presentation does not constitute or contain an offer or invitation or recommendation or solicitation for the sale or purchase of securities, interests or assets in or of the Company and neither this document nor anything contained herein shall form the basis of, or be relied upon in connection with, any contract or commitment whatsoever. Any decision to purchase or subscribe for securities in any offering must be made solely on the basis of the information contained in the prospectus or offering circular issued by the company in connection with such offerings. All the information in this Presentation has been provided by the Company and has not been independently verified. No representation or warranty, express or implied, is or will be made in or in relation to, and no responsibility or liability is or will be accepted by the Company or any of its subsidiaries as to the appropriateness, accuracy, completeness or reliability of, this Presentation or any other written or oral information made available to any interested party or its advisers and any liability therefore is hereby expressly disclaimed. And no reliance should be placed on the accuracy, fairness, completeness or correctness of the information contained in this Presentation. This Presentation is only being made available to parties who have signed and returned a confidentiality agreement and recipients are therefore bound by the confidentiality agreement in respect of all information contained herein. This Presentation is strictly private and confidential and must not be copied, reproduced, distributed or passed (directly or indirectly, in whole or in part) to any other person at any time, whether for gain or otherwise, without the prior written consent of the Company. By accepting this Presentation, the recipient has agreed to be bound by the limitations contained herein. This Presentation has been delivered to interested parties for information purposes only and upon the express understanding that such parties will use it only for the purposes set forth above. By accepting this Presentation the recipient has agreed, upon request and at the recipient’s own costs, to return promptly all material received from the Company (including this Presentation) without retaining any copies. In furnishing this Presentation, the Company and its subsidiaries undertake no obligation to provide the recipient with access to any additional information or to update this Presentation or to correct any inaccuracies therein which may become apparent, and reserve the right, without advance notice, to change the procedure for the sale of securities, interests or assets in or assets of the Company or terminate negotiations at any time prior to the signing of any binding agreement for the sale of securities, interests or assets in or of the Company. This Presentation is directed only at persons which are not “U.S. persons”( “U.S. Persons") as defined under Regulation S of the United States Securities Act of 1933, as amended and, in addition, which are lawfully able to receive this document under the laws of the jurisdictions in which they are located or other applicable laws( “relevant persons”). This document must not be acted on or relied on by persons which are not relevant persons. Any investment or investment activity to which this Presentation relates are available only to relevant persons and will be engaged in only with relevant persons. By accepting this Presentation the recipient represents and warrants that (a) it is lawfully able to receive this document under the laws of the jurisdiction in which it is located or other applicable laws; (b) it is not a U.S. Person, (c) this Presentation is furnished to it outside the United States, and (d) it will not reproduce, publish, disclose, redistribute or transmit this Presentation directly or indirectly, into the United States or to any U.S. Person either within or outside of the recipient’s organisation. The distribution of this Presentation may be restricted by law in certain jurisdictions and persons in whose possession this document comes should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the laws of any such jurisdictions. Any prospective purchaser interested in purchasing securities, interests or assets in or of the Company or evaluating the Company is recommended to seek its own financial and other professional advice. 2 CONTENT 1. The Group's Future Value System 2. Results Overview 3. R&D and Innovation 4. Marketing and Sales 5. M&A and International Collaborations 6. Manufacturing Facilities 7. Financial Review 8. Future Prospects 3 Chapter One The Group's Future Value System 4 The Group's overall development strategy Mission： Innovation serves human health Vision: Leading with innovation and R&D, by means of investment, incubation, M&A, spin-offs and other strategic planning and core-value creation methods, to become a leading international pharmaceutical group in China. Take investment, joint Take the Group's wholly- Incubate successful Cooperation with external venture, and equity owned holding subsidiary companies parties to realize value-add participation in other companies as core-value operating independently system companies as extension system as value amplification • Benxi Hengkang systems • Beijing Sihuan system • Changchun Xiangtong • Jilin Sichang • Jilin Suhuan • Xuanzhu Group • Zesheng Environmental • PharmaDax • Jilin Jinsheng • Jilin Huisheng Protection Pharmaceutical • Honghe Pharmaceutical • Jilin Aokang • Tonghua Tianshi • ChemPion • Beijing Aohe • Jilin Kangtong • Chongqing West District • Zhongrui Pharmaceutical • Innovative R&D • Beijing Ruiye Hospital • STRIDES, India • Sihuan Medical Beauty • Huaiyin Hospital • HETERO, India Focus on rapidly developing therapeutic areas: cardiocerebrovascular, oncology, diabetes, metabolic diseases, anti-infection Core Advantages： • Innovation-driven, imitation and creation co-exist, and a number of carefully incubated high-quality product development platforms have achieved good performance progress • Possess a rich and high-quality pipeline of R&D products covering multiple major therapeutic areas • Comprehensive, professional and efficient academic marketing platform • High efficiency, low cost, modern manufacturing facilities covering multiple therapeutic areas • Abundant cash balances and stable financial conditions provide sufficient support for the steady development and rapid expansion of the Group 5 The Group's future value system Xuanzhu Jilin Group Huisheng Beijing Jilin Ruiye Value Kangtong Amplification System Jilin Sihuan Aokang Aesthetic Beijing Sihuan Benxi Jilin Honghe Jilin Hengkang Sichang Pharma Sihuan Core value PharmaD system Changchun ax Xiangtong Beijing Jilin Aohe Jinsheng Value Innovative Value-add Extension External Zesheng ChemPion R&D Environmental System Cooperation Protection Huaiyin Hetero Zhong Hospital Tonghua Rui Chongqing Tianshi Strides West District Hospital 6 Chapter Two Results Overview 7 Results overview Results Review From continuing operations • Revenue decreased by 36.4% year-on-year and 13.6% Revenue R&D expenditure period-to-period, to approximately RMB1.05 billion 1.05 billion 392.7 million • R&D expenditure and related activities increased by 43.9% year-on-year to approximately RMB392.7 million, representing 37.2% of total revenue • Profit attributable to company owners of the Company turned into profit, approximately RMB170.5 million Profit attributable to owners Net cash • The gross profit margin is 74.5% of the Company 4.34 billion • 170.5 million The Group has maintained a strong financial position and has recorded a net cash of over approximately RMB4.34 billion Marketing and Sales Nicotinamide Huineng Mainuokang Shucheng Diprophylline for injection injection +187.2% +137.3% +98.2% +116.2% +162.6% Multiple products maintain rapid growth 1H19 1H20 1H19 1H20 1H19 1H20 1H19 1H20 1H19 1H20 8 Results highlight Major R&D project progress Progress of major cooperation projects Anaprazole sodium, a self-developed innovative patented drug Xuanzhu Biopharmaceutical introduced CMG-SDIC as a for digestive system, commenced phase III clinical trials shareholder of the company with RMB800 million in capital Data from Janagliflozin’s phase III clinical trials has been locked and is currently been analysed Associated company Beijing Ruiye introduced a total of RMB200 million from two investors Insulin Degludec commenced phase III clinical trials Equity investment in Zhongrui Pharmaceutical to increase the Rivastigmine hydrogen tartrate capsule and levetiracetam Group’s API production capacity tablet have been granted production approval Midazolam oromucosal solution has been granted registration Equity investment in Champion to strengthen the Group's approval R&D capabilities in API enzymatic process, continuous flow process technology, etc. Paediatric compound amino acid injection (18AA-II) obtained Signed a cooperation agreement with Hetero to strengthen drug registration approval R&D in the field of cardiovascular, central nervous system and anti-infection Azithromycin capsule was selected
Load more

Recommended publications
  • Feature Gater Inage
    29 Feature II China in Chiba: Das Landhaus Aishinkakurafuketsukagū in Inage Nicht weit vom Bahnhof Keisei Inage liegt auf einem Hügel ein großer Shintō-Schrein, der Sengen Jinja. Früher bot sich von dort oben ein herrlicher Blick auf die Tokyoter Bucht ‒ heute ist von ihr allerdings nichts mehr zu sehen, wurden doch Polder ange- legt und freie Flächen bebaut. In unmittelbarer Nähe zum Schreingelände verläuft nun die Autobahn zwischen Tokyo und Chiba, und das Haupttor des Schreins, das vor dem Krieg noch im Meerwasser stand, liegt nun am Rande eines Wohnviertels. Trotzdem ist der Sengen-Schrein gut besucht, vor allem an Neujahr und am wichtigsten Festtag des Schreines Mitte Juli (in diesem Jahr am 14./15. Juli). Was die meisten Pilger nicht bemerken, weil es kaum zu sehen ist, ist ein niedliches kleines Häuschen auf der rechten Seite des Hügels, wenn man in Richtung Bucht sieht. Die Bescheidenheit des Häuschens täuscht aber, wohnte hier doch eine Zeit lang Pujie, der jüngere Bruder des letzten Kaisers von China und später der Mandschurei. Wenn man den Film Der letzte Kaiser von Bertolucci gesehen hat, ist kaum zu glauben, dass der Bruder des Kaisers Puyi, der in der Pracht der Verbotenen Stadt von Peking leb- te, in den dreißiger Jahren hier eine Weile sein Leben verbracht hat. In starkem Kont- rast zum weitläufigen Tian’anmen-Platz liegt das Häuschen in einer kleinen Gasse. Auf einem unscheinbaren Schild steht Aishinkakurafuketsukagū (愛新覚羅溥傑仮寓), also „Vorübergehende Residenz (kari no gū) von Aishinkakura Fuketsu (Pujie)“. Heute ist es ein Museum der Stadt Chiba. Mit der chinesischen Revolution von 1911 und der Gründung der chinesischen Repub- lik unter Sun Yat-sen hatte der letzte Kaiser Puyi als junger Mann noch eine erstaunli- che Laufbahn vor sich.
    [Show full text]
  • Making the Palace Machine Work Palace Machine the Making
    11 ASIAN HISTORY Siebert, (eds) & Ko Chen Making the Machine Palace Work Edited by Martina Siebert, Kai Jun Chen, and Dorothy Ko Making the Palace Machine Work Mobilizing People, Objects, and Nature in the Qing Empire Making the Palace Machine Work Asian History The aim of the series is to offer a forum for writers of monographs and occasionally anthologies on Asian history. The series focuses on cultural and historical studies of politics and intellectual ideas and crosscuts the disciplines of history, political science, sociology and cultural studies. Series Editor Hans Hågerdal, Linnaeus University, Sweden Editorial Board Roger Greatrex, Lund University David Henley, Leiden University Ariel Lopez, University of the Philippines Angela Schottenhammer, University of Salzburg Deborah Sutton, Lancaster University Making the Palace Machine Work Mobilizing People, Objects, and Nature in the Qing Empire Edited by Martina Siebert, Kai Jun Chen, and Dorothy Ko Amsterdam University Press Cover illustration: Artful adaptation of a section of the 1750 Complete Map of Beijing of the Qianlong Era (Qianlong Beijing quantu 乾隆北京全圖) showing the Imperial Household Department by Martina Siebert based on the digital copy from the Digital Silk Road project (http://dsr.nii.ac.jp/toyobunko/II-11-D-802, vol. 8, leaf 7) Cover design: Coördesign, Leiden Lay-out: Crius Group, Hulshout isbn 978 94 6372 035 9 e-isbn 978 90 4855 322 8 (pdf) doi 10.5117/9789463720359 nur 692 Creative Commons License CC BY NC ND (http://creativecommons.org/licenses/by-nc-nd/3.0) The authors / Amsterdam University Press B.V., Amsterdam 2021 Some rights reserved. Without limiting the rights under copyright reserved above, any part of this book may be reproduced, stored in or introduced into a retrieval system, or transmitted, in any form or by any means (electronic, mechanical, photocopying, recording or otherwise).
    [Show full text]
  • Pharma China0409-285.P65
    TM C O N T E N T S ○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○ ○○○ I s s u e Editorial Mentholatum sues XiAn Meichen over Market Dynamics Brew New Order for trademark infringements 14 Chinese Pharma 2 API/Bulk Drugs 32 News in Focus Huaxing expands capacity of Amoxicillin MOH releases results of the 4th and 6-APA 14 APRIL National Health Service Survey 4 NCPG/DSM likely to build major The Market antibiotic API facility in Changchun 14 2 0 0 9 Data Snaptshot: Chinese OTC Shandong Antibiotics granted Germany healthcare market 5 GMP certification 15 Nicholas Hall reports slower growth Hisun sees profits up sharply in 2008 15 of OTC GI market in China 5 Changzhou Yabang-QH builds new In This Issue Industry News cGMP API plant with help from J&J 15 Chinese pharma industry perfor- Shijiazhuang Pharma receives EDQM MNCs report another year of mance in 2008 and outlook in 2009 5 certification for Vitamin B12 15 sharp revenue growth in China MNCs report another year of sharp India likely to investigate China’s 6-APA 15 Many MNCs experienced growth 20% revenue growth in China 6 MOC issues list of authorized exporters or more in China last year amid global MNCs positions for the huge diabetes of ephedrine drugs 15 slowdown P6 market potential in China 6 Data Snapshot - COS certifications and Harbin Pharma reconsiders Chinese producers likely to emerge DMFs held by Chinese companies 16 overseas IPO as global players of recombinant Chinese API in 2008 – Output and Export In preparation, Harbin Pharmaceutical human insulin 6 Volumes Down 16 Group is working on major and minor M&A is likely to intensify for retail Product and R&D News acquisitions this year P8 pharmacy sector in 2009 7 AOB to initiate clinical trials of TCM drug Pfizer opens new sterile facility Guangzhou introduces online for UI in the U.S.
    [Show full text]
  • Preliminary Pages
    UNIVERSITY OF CALIFORNIA Los Angeles Ascending the Hall of Great Elegance: the Emergence of Drama Research in Modern China A dissertation submitted in partial satisfaction of the requirements for the degree Doctor of Philosophy in History by Hsiao-Chun Wu 2016 © Copyright by Hsiao-Chun Wu 2016 ABSTRACT OF THE DISSERTATION Ascending the Hall of Great Elegance: the Emergence of Drama Research in Modern China by Hsiao-Chun Wu Doctor of Philosophy in History University of California, Los Angeles, 2016, Professor Andrea Sue Goldman, Chair This dissertation captures a critical moment in China’s history when the interest in opera transformed from literati divertissement into an emerging field of scholarly inquiry. Centering around the activities and writings of Qi Rushan (1870-1962), who played a key role both in reshaping the modes of elite involvement in opera and in systematic knowledge production about opera, this dissertation explores this transformation from a transitional generation of theatrical connoisseurs and researchers in early twentieth-century China. It examines the many conditions and contexts in the making of opera—and especially Peking opera—as a discipline of modern humanistic research in China: the transnational emergence of Sinology, the vibrant urban entertainment market, the literary and material resources from the past, and the bodies and !ii identities of performers. This dissertation presents a critical chronology of the early history of drama study in modern China, beginning from the emerging terminology of genre to the theorization and the making of a formal academic discipline. Chapter One examines the genre-making of Peking Opera in three overlapping but not identical categories: temporal, geographical-political, and aesthetic.
    [Show full text]
  • China Pharmaceutical Newsletter
    Volume VII 2011 CHINA PHARMACEUTICAL ڵNEWSLETTER З֡Ԛ哦֡ଢ଼рࡗЗ แྼჯ)ཀৄDž዆ᄱᆶ၌ࠅິ SFDA Commissioner Shao Mingli SFDA Deputy Commissioner Wu Zhen of NPC Standing Committee attended the met with new Cuban Ambassador to meets the Head of Iran's Innovation and meeting. Chen Zhu, the Health Minister China On September 29, 2011, Shao Technology Cooperation Center On the & Chairman of the Forum attended the Mingli, Commissioner of SFDA met morning of September 6, 2011, Wu Zhen, forum and delivered a speech. with Mr. ALberto Jesus Blanco Silva, the SFDA Deputy Commissioner, met with the Chen Zhu said in his speech, through new Cuban Ambassador Extraordinary visiting Mr. Hamidreza Amirinia, Head of 30 years of reform and opening up, and Plenipotentiary to China, and his Innovation and Technology Cooperation China's GDP has maintained a 10% entourage in Beijing. The two sides Center of Iran. Both parties exchanged growth in 30 consecutive years, and held in-depth discussions on further views on enhancing mutual exchanges and created an economic miracle. In 2010, strengthening the bilateral cooperation in understanding, and promoting cooperation China's GDP had ranked second in the WKH¿HOGVRIELRORJLFDl products and drug LQWKH¿HOGRIWUDGLWLRQDO&KLQHVHPHGLFLQH world. In the 21st century, the Chinese safety supervision. (September 30, 2011) and biopharmaceuticals. (September 8, 2011) Government pays more attention to social SFDA Deputy Commissioner Wu development, taking the alleviation of SFDA Deputy Commissioner Bian Zhen meets the delegation of MHLW On poverty and improvement of health care, Zhenjia attends the APEC LSIF Drug the morning of August 23, 2011, Wu Zhen, education, housing, and employment, etc.
    [Show full text]
  • The University of Chicago Manchurian Atlas
    THE UNIVERSITY OF CHICAGO MANCHURIAN ATLAS: COMPETITIVE GEOPOLITICS, PLANNED INDUSTRIALIZATION, AND THE RISE OF HEAVY INDUSTRIAL STATE IN NORTHEAST CHINA, 1918-1954 A DISSERTATION SUBMITTED TO THE FACULTY OF THE DIVISION OF THE SOCIAL SCIENCES IN CANDIDACY FOR THE DEGREE OF DOCTOR OF PHILOSOPHY DEPARTMENT OF HISTORY BY HAI ZHAO CHICAGO, ILLINOIS DECEMBER 2015 For My Parents, Zhao Huisheng and Li Hong ACKNOWLEDGEMENTS It has been an odyssey for me. The University of Chicago has become both a source of my intellectual curiosity and a ladder I had to overcome. Fortunately, I have always enjoyed great help and support throughout the challenging journey. I cannot express enough thanks to my academic advisors—Professor Bruce Cumings, Professor Prasenjit Duara, and Professor Guy Alitto—for their dedicated teaching, inspiring guidance and continued encouragement. I have also benefited immensely, during various stages of my dissertation, from the discussions with and comments from Professor Salim Yaqub, Professor James Hevia, Professor Kenneth Pomeranz, and Professor Jacob Eyferth. Professor Dali Yang of Political Sciences and Professor Dingxin Zhao of Sociology provided valuable insights and critiques after my presentation at the East Asia Workshop. My sincere thanks also goes to Professor Shen Zhihua at the East China Normal University who initiated my historical inquiry. I am deeply indebted to my friends and colleagues without whom it would not have been possible to complete this work: Stephen Halsey, Paul Mariani, Grace Chae, Suzy Wang, Scott Relyea, Limin Teh, Nianshen Song, Covell Meyskens, Ling Zhang, Taeju Kim, Chengpang Lee, Guo Quan Seng, Geng Tian, Yang Zhang, and Noriko Yamaguchi.
    [Show full text]
  • The University of Chicago Sound Images, Acoustic
    THE UNIVERSITY OF CHICAGO SOUND IMAGES, ACOUSTIC CULTURE, AND TRANSMEDIALITY IN 1920S-1940S CHINESE CINEMA A DISSERTATION SUBMITTED TO THE FACULTY OF THE DEVISION OF THE HUMANITIES IN CANDIDACY FOR THE DEGREE OF DOCTOR OF PHILOSOPHY DEPARTMENT OF CINEMA AND MEDIA STUDIES BY LING ZHANG CHICAGO, ILLINOIS JUNE 2017 Table of Contents Acknowledgements………………………………………………………………………………………iii Abstract…………………………………………………………………………………………………. x Introduction……………………………………………………………………………………………… 1 Chapter One Sound in Transition and Transmission: The Evocation and Mediation of Acoustic Experience in Two Stars in the Milky Way (1931) ...................................................................................................................................................... 20 Chapter Two Metaphoric Sound, Rhythmic Movement, and Transcultural Transmediality: Liu Na’ou and The Man Who Has a Camera (1933) …………………………………………………. 66 Chapter Three When the Left Eye Meets the Right Ear: Cinematic Fantasia and Comic Soundscape in City Scenes (1935) and 1930s Chinese Film Sound… 114 Chapter Four An Operatic and Poetic Atmosphere (kongqi): Sound Aesthetic and Transmediality in Fei Mu’s Xiqu Films and Spring in a Small Town (1948) … 148 Filmography…………………………………………………………………………………………… 217 Bibliography………………………………………………………………………………………… 223 ii ACKNOWLEDGEMENTS Over the long process of bringing my dissertation project to fruition, I have accumulated a debt of gratitude to many gracious people who have made that journey enjoyable and inspiring through the contribution of their own intellectual vitality. First and foremost, I want to thank my dissertation committee for its unfailing support and encouragement at each stage of my project. Each member of this small group of accomplished scholars and generous mentors—with diverse personalities, academic backgrounds and critical perspectives—has nurtured me with great patience and expertise in her or his own way. I am very fortunate to have James Lastra as my dissertation co-chair.
    [Show full text]
  • The Making of China's Peace with Japan
    SELECTED BIBLIOGRAPHY SOURCES IN CHINESE Books Jin, Chongji. ed. (principal editor). Zhou Enlai zhuan 1898–1949 (Biography of Zhou Enlai 1898–1949). Edited by Zhonggong-zhongyang wenxian-yanjiushi. Beijing: Renmin-chubanshe and Zhongyang wenxian-chubanshe, 1989. Jin, Chongji. ed. (principal editor). Zhou Enlai zhuan (Biography of Zhou Enlai). 2 vols. Edited by Zhonggong-zhongyang wenxian-yanjiushi. Beijing: Zhongyang wenxian-chubanshe, 1998. Jinian Zhou Enlai chuban-faxing weiyuanhui. ed. Ribenren xinmuzhong de Zhou Enlai (Zhou Enlai in the Hearts of the Japanese). Trans by Liu Shouxu. Beijing: Zhonggong-zhongyang dangxiao-chubanshe, 1991. Li, Enmin. Zhongri minjian jingji waijiao (Sino-Japanese Private Economic Diplomacy). Beijing: Renmin-chubanshe, 1997. Li, Rongde. Liao Chengzhi. Singapore: Yongsheng-shuju, 1992. Liao Chengzhi ziliaoji (Documents on Liao Chengzhi). Hong Kong: Taozhai- shuwu, 1973. Liu, Wusheng. Zhou Enlai de wannian suiyue (Late Years of Zhou Enlai). Hong Kong: Sanlian-shudian, 2006. Sun, Pinghua. Wode lulishu (My Autobiography). Beijing: Shijie-zhishi chu- banshe, 1998. Wang, Junyan. Da-waijiaojia Zhou Enlai (Zhou Enlai: A Great Diplomat). Beijing: Jingji-ribao chubanshe, 1998. Wang, Xuanren. Nibuzhidao de Zhou Enlai (Zhou Enlai That You Do Not Know). Taipei: Wanyuan-tushu, 2005. © The Author(s) 2017 271 M. Itoh, The Making of China’s Peace with Japan, DOI 10.1007/978-981-10-4008-5 272 SELECTED BIBLIOGRAPHY Wang, Yongxiang and Takahashi, Tsuyoshi. eds. Riben liuxue-shiqi de Zhou Enlai (Zhou Enlai During his Study Period in Japan). Beijing: Zhongyang wenxian- chubanshe, 2001. Wu, Xuewen. Fengyu yinqing: Wosuo jingli de Zhongri guanxi (Wind, Rain, Cloud, Sun: My Autobiography and Sino-Japanese Relations). Beijing: Shijie-zhishi chubanshe, 2002.
    [Show full text]
  • Download Table of Contents [PDF 1
    Advances in Biopharmaceutical Technology in China, Second Edition October 2018 Editors: Vicky (Qing) Xia, Leo (Yang) Cai BioPlan Associates, Inc. Rockville, MD Society for Industrial Microbiology and Biotechnology Fairfax, VA BioPlan Associates, Inc. 2275 Research Blvd., Ste. 500 Rockville MD 20850 USA 301-921-9074 www.bioplanassociates.com and Society for Industrial Microbiology and Biotechnology 3929 Old Lee Highway Suite 92A Fairfax, VA 22030-2421 703-691-3357 www.simbhq.org Copyright © 2018 BioPlan Associates, Inc. All rights reserved, including the right of reproduction in whole or in part in any form. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the written permission of the publisher. For information on special discounts or permissions contact BioPlan Associates, Inc. at 301- 921-5979, or [email protected] Editors: Vicky (Qing) Xia, Leo (Yang) Cai Project Director: Donnie E. Gillespie U.S. Editor: Terrell R. Otis Cover Design: LI Huijun Text Design: Esperance Shatarah, ES Design ISBN 978-1-934106-34-1 Front Cover Photo Courtesy of WuXi, by permission ii Acknowledgment This project would not have been possible without the exceptional efforts of the many people involved. In particular, we would like to thank our reviewers, whose expertise ensured this volume addressed today’s most important issues: ■ Tiffany M. Bauguess (Beeson), Consultant, MScGlobal Trials HK ■ Randy Berholz, Executive Vice President, Corporate Development and General Counsel, Innovus Pharmaceuticals, Inc. ■ David Deere, Chief Commercial Officer, PaizaBio ■ Changming Fang, Director of Biology and Drug Discovery, FronThera US Pharmaceuticals ■ Steve Ferguson, Chair, Department of Technology Transfer, Foundation for Advanced Education in the Sciences (FAES) Graduate School ■ Sean Hu, Founder, mAbKey Therapeutics ■ Charles (Changhui) Li, MS MBA, Chief Business Officer, Zhejiang Hopstem Biotech- nology Co., Ltd.
    [Show full text]
  • Global Factory List As of August 3Rd, 2020
    Global Factory List as of August 3rd, 2020 Target is committed to providing increased supply chain transparency. To meet this objective, Target publishes a list of all tier one factories that produce our owned-brand products, national brand products where Target is the importer of record, as well as tier two apparel textile mills and wet processing facilities. Target partners with its vendors and suppliers to maintain an accurate factory list. The list below represents factories as of August 3rd, 2020. This list is subject to change and updates will be provided on a quarterly basis. Factory Name State/Province City Address AMERICAN SAMOA American Samoa Plant Pago Pago 368 Route 1,Tutuila Island ARGENTINA Angel Estrada Cla. S.A, Buenos Aires Ciudad de Buenos Aires Ruta Nacional N 38 Km. 1,155,Provincia de La Rioja AUSTRIA Tiroler Glashuette GmbH Werk: Schneegattern Oberosterreich Lengau Kobernauserwaldstrase 25, BAHRAIN WestPoint Home Bahrain W.L.L. Al Manamah (Al Asimah) Riffa Building #1912, Road # 5146, Block 951,South Alba Industrial Area, Askar BANGLADESH Campex (BD) Limited Chittagong zila Chattogram Building-FS SFB#06, Sector#01, Road#02, Chittagong Export Processing Zone,, Canvas Garments (Pvt.) Ltd Chittagong zila Chattogram 301, North Baizid Bostami Road,,Nasirabad I/A, Canvas Building Chittagong Asian Apparels Chittagong zila Chattogram 132 Nasirabad Indstrial Area,Chattogram Clifton Cotton Mills Ltd Chittagong zila Chattogram CDA plot no-D28,28-d/2 Char Ragmatia Kalurghat, Clifton Textile Chittagong zila Chattogram 180 Nasirabad Industrial Area,Baizid Bostami Road Fashion Watch Limited Chittagong zila Chattogram 1363/A 1364 Askarabad, D.T. Road,Doublemoring, Chattogram, Bangladesh Fortune Apparels Ltd Chittagong zila Chattogram 135/142 Nasirabad Industrial Area,Chattogram KDS Garment Industries Ltd.
    [Show full text]
  • Pharmaceutical Innovation in the APAC Region
    Special report Pharmaceutical innovation in the APAC region A quantitative company ranking and future outlook Country/ Major Pharma Early-stage Drug Rank Company Maturity Total Score Region HQ (Top 50 by global revenue) Partnering Development 가장 혁신적인 1 Daiichi Sankyo Co Ltd Japan 410 320 135 865 대형 제약사 2 Takeda Pharmaceutical Co Ltd Japan 395 320 135 850 Rank 1-18 3 Eisai Co Ltd Japan 350 320 135 805 4 Astellas Pharma Inc Japan 345 320 135 800 5 Otsuka Holdings Co Ltd Japan 325 315 135 775 6 Shionogi & Co Ltd Japan 320 315 125 760 6 CSL Ltd Australia 345 310 105 760 8 Ono Pharmaceutical Co Ltd Japan 320 310 125 755 9 Mitsubishi Chemical Holdings Corp Japan (Mitsubishi Tanabe) 300 315 125 740 9 Kirin Holdings Co Ltd Japan (Kyowa Hakko Kirin) 315 300 125 740 11 Hanmi Pharmaceutical Co Ltd South Korea 325 295 115 735 12 Daewoong Pharmaceutical Co Ltd South Korea 305 300 95 700 13 Sumitomo Chemical Co Ltd Japan 265 305 125 695 14 FUJIFILM Holdings Corp Japan 265 300 125 690 15 Kyorin Holdings Inc Japan 280 280 105 665 16 Teijin Ltd Japan 250 275 115 640 17 Japan Tobacco Ltd Japan 230 260 115 605 18 Lupin Ltd India 185 280 125 590 18 Maruho Co Ltd Japan 200 265 125 590 Shanghai Fosun Pharmaceutical 18 Mainland China 175 305 110 590 (Group) Co Ltd Note: Scores do not reflect recent changes in company ownership, e.g., divestiture of CJ Healthcare to Korea Kolmar Holdings in 2018.
    [Show full text]
  • Simcere Pharmaceutical Group Limited 先聲藥業集團有限公司 (The “Company”) (A Company Incorporated in Hong Kong with Limited Liability)
    The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of Simcere Pharmaceutical Group Limited 先聲藥業集團有限公司 (the “Company”) (a company incorporated in Hong Kong with limited liability) WARNING The publication of this Application Proof is required by The Stock Exchange of Hong Kong Limited (the “Exchange”) and the Securities and Futures Commission (the “Commission”) solely for the purpose of providing information to the public in Hong Kong. This Application Proof is in draft form. The information contained in it is incomplete and is subject to change which can be material. By viewing this document, you acknowledge, accept and agree with the Company, its joint sponsors, advisers or members of the underwriting syndicate that: (a) this document is only for the purpose of providing information about the Company to the public in Hong Kong and not for any other purposes. No investment decision should be based on the information contained in this document; (b) the publication of this document or supplemental, revised or replacement pages on the Exchange’s website does not give rise to any obligation of the Company, its joint sponsors, advisers or members of the underwriting syndicate to proceed with an offering in
    [Show full text]